Comparative Pharmacology
Head-to-head clinical analysis: ANGIO CONRAY versus GADOTERATE MEGLUMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIO CONRAY versus GADOTERATE MEGLUMINE.
ANGIO-CONRAY vs GADOTERATE MEGLUMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angio-Conray (iothalamate meglumine) is a radiopaque contrast agent that attenuates X-rays, providing vascular opacification for angiographic procedures.
Gadoterate meglumine is a paramagnetic contrast agent that increases the relaxation rate of water protons in tissues, thereby enhancing image contrast in magnetic resonance imaging (MRI). It is a macrocyclic gadolinium-based contrast agent (GBCA) with high thermodynamic stability and kinetic inertness, reducing the risk of gadolinium dissociation.
Intravenous: 0.5-1 mL/kg (maximum 100 mL) of a 60% solution for computed tomography; intra-arterial: varies by procedure, typically 5-80 mL of 60% or 76% solution.
0.2 mL/kg (0.1 mmol/kg) intravenously as a single bolus injection.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours; prolonged in renal impairment.
Terminal elimination half-life approximately 1.5–2 hours in patients with normal renal function; prolonged in renal impairment (up to 12–34 hours in severe impairment).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal (99% excreted unchanged in urine within 24 hours); biliary/fecal elimination negligible (<1%).
Category C
Category C
Contrast Agent
Contrast Agent